Succinobucol

CAS : 216167-82-7

Ref. 3D-FS27918

Informations sur le produit

• Nom: Succinobucol
• Synonymes: Butanedioic acid 1-[4-[[1-[[3,5-bis(1 ,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1 ,1-dimethylethyl)phenyl] ester, 4-[2,6-Di-Tert-Butyl-4-({2-[(3,5-Di-Tert-Butyl-4-Hydroxyphenyl)Sulfanyl]Propan-2-Yl}Sulfanyl)Phenoxy]-4-Oxobutanoic Acid, Agi-1067, Agz-1067, Butanedioic acid, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester, Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester, Probucol monosuccinate

Description

Succinobucol is an experimental drug that may be used for the treatment of atherosclerotic lesions. It has been shown to inhibit the atp-binding cassette transporter and induce mitochondrial membrane potential, thereby inhibiting receptor activity in cardiac cells. This drug also inhibits toll-like receptor 4 (TLR4) expression and chemoattractant protein production, which may be responsible for its anti-inflammatory effects. Succinobucol has also been shown to inhibit ester linkages and enzymes involved in metabolic disorders, such as diabetes mellitus type 2.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 616.92 g/mol
• Formule: C₃₅H₅₂O₅S₂
• Degré de pureté: Min. 95 Area-%
• Couleur/Forme: Powder